Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on May 22, 2014. The filing addresses corporate governance changes regarding the compensation of non-executive directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director compensation policy updates.
Material Changes
On May 22, 2014, the Board of Directors approved a new non-executive director compensation policy. While base annual cash retainers remain unchanged ($85,000 for the Chairman, $65,000 for the Vice Chair, and $45,000 for other members), the policy introduces new annual cash retainers for committee chairs:
- Audit Committee Chair: $12,000
- Compensation and Organization Development Committee Chair: $10,000
- Nominating and Corporate Governance Committee Chair: $8,000
Additionally, non-executive directors are entitled to an annual grant of options to purchase up to 9,000 shares of common stock, vesting fully on the first anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the new compensation policy.
Investor Verification Checklist
- Verify the total number of non-executive directors to calculate the aggregate impact of the new committee chair retainers.
- Confirm the total number of shares reserved for the annual option grants (9,000 per director) and the associated dilution impact.
- Review the company's most recent 10-K or 10-Q for actual financial performance, as this 8-K contains no financial data.